STOCK TITAN

Spectral AI Inc - MDAIW STOCK NEWS

Welcome to our dedicated news page for Spectral AI (Ticker: MDAIW), a resource for investors and traders seeking the latest updates and insights on Spectral AI.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Spectral AI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Spectral AI's position in the market.

Rhea-AI Summary
Spectral AI, Inc. appoints Jeremiah A. Sparks as Chief Commercialization Officer to drive commercialization of DeepView, an innovative wound management solution. Sparks brings over 20 years of medical device marketing experience, including global marketing and business strategy. His track record includes successful market assessments, commercialization plans, and product launches at major companies like Johnson & Johnson and Allergan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.39%
Tags
management AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) expects its 2023 Research & Development revenue of $18.1 million to increase to $28.0 million in 2024. Commercialization for DeepView AI®-Burn indication in the UK is underway, with revenue expected in 2H 2024. The company plans additional regulatory submissions in the US and UK for DeepView™ System burn and diabetic foot ulcer indications. Spectral AI highlights progress in product development, clinical trials, and financial results, aiming for commercial revenue across multiple platforms within the next three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) secures a $30.0 million prepaid advance and standby equity purchase agreement to support commercialization and research activities. The agreement with a long-only investor includes a fixed conversion price of $3.16 and provides flexibility for additional draws. CEO Peter M. Carlson highlights the importance of this funding for strategic imperatives and commercialization initiatives, emphasizing recent milestones in the U.K. and the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.24%
Tags
AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announced a $1 million investment from its largest shareholder into its subsidiary Spectral IP, focusing on advancing intellectual property in the AI ecosystem. The investment aims to unlock additional value for shareholders and accelerate innovation in medical diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.66%
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) will report financial results for Q4 and full year 2023 on March 27, 2024. The company focuses on AI medical diagnostics for wound care. Investors can join the conference call to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.05%
Tags
-
Rhea-AI Summary
Spectral AI, Inc. (MDAI) secures a new $500,000 contract with the Defense Health Agency and the US Army Medical Material Development Activity for the development of the handheld version of DeepView™ Wound Imaging System. The Company has received over $149 million in non-dilutive financing in the past six months, bringing the total government support to over $250 million. The contract aims to optimize the device's functionality and size for combat readiness and potential use in home health care, reinforcing Spectral AI's position as a leader in AI-driven healthcare innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.56%
Tags
AI
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) forms a subsidiary to focus on advancing intellectual property in the AI healthcare sector, aiming to enhance shareholder value through patents and trade secrets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. appoints Peter M. Carlson as CEO, transitioning Wensheng Fan to Chief Innovation Strategist. The Company announces preliminary 2023 R&D revenue of $18 million and reaffirms $28 million revenue guidance for 2024. Spectral AI highlights first quarter momentum and key milestones in commercialization of AI-powered wound care technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
management AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announces participation in investor conferences to showcase their AI technology for medical diagnostics in wound care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
conferences AI
Rhea-AI Summary
Spectral AI, Inc. (MDAI) announces the UKCA authorization for its DeepView AI®-Burn predictive software, allowing for faster burn wound diagnosis. Revenue from UK commercialization in 2024 is expected to contribute to the Company's $28 million revenue guidance. The technology boasts 92% accuracy in distinguishing healthy and damaged tissue, potentially revolutionizing burn wound management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
Spectral AI Inc

Nasdaq:MDAIW

MDAIW Rankings

MDAIW Stock Data

7.41M
Medical Devices
Healthcare
Link
United States
Dallas